Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials. He instigated and helped to lead the large-scale CANTOS trial that provided clinical validation of the role of inflammation in atherosclerosis.
An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in top ranked medical journals. He is the Editor-in Chief for the 12th edition of Braunwald’s Heart Disease
Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and Doctorat honoris causa from the Université de Lille, France , Université Laval in Québec, Canada, and Doctor Medicinæ Honoris Causa degree from Goethe University, Frankfurt am Main, Germanypeter libby

Contributions

Inflammation in a Translational Perspective - WebinarWebinars on-demandPanel Discussion: How can we reduce cardiovascular risk targeting inflammation via IL-6_91st EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_How are systemic inflammation and IL-6 implicated in atherosclerosis and its complications?91st EAS Congress 2023How can we reduce cardiovascular risk targeting inflammation via IL-6_Panel Discussion: IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis91st EAS Congress 2023IAS/EAS joint session - Cardiometabolic traits - The next battleground in AtherosclerosisInflammation in the metabolic syndrome91st EAS Congress 2023IAS/EAS joint session - Cardiometabolic traits - The next battleground in AtherosclerosisModern approach to dyslipidemia91st EAS Congress 2023Integrating the many players of cardiovascular riskClonal Hematopoiesis and Atherosclerosis90th EAS Congress 2022Advanced clinical seminar: Changing face of atherosclerosis(AtherothrombosisCV risk factors: Others)Clonal Hematopoiesis and Atherosclerosis90th EAS Congress 2022Advanced clinical seminar: Changing face of atherosclerosis(AtherothrombosisCV risk factors: Others)Anti-Inflammatory Therapy for Atherosclerosis - Theory and Practice86th EAS Congress 2018The case for immune cells - An expanded cardiovascular continuum85th EAS Congress 2017The 2013 Anitschkow Lecture81st EAS Congress 2013